AG 4263

Drug Profile

AG 4263

Alternative Names: AG-4263; AnergiX.RA

Latest Information Update: 15 Aug 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Corixa Corporation
  • Developer Corixa Corporation; Organon
  • Class Antirheumatics
  • Mechanism of Action T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 17 May 2005 No development reported - Phase-II for Rheumatoid arthritis in USA (IV)
  • 30 Jul 2002 This compound is still in active development
  • 24 Jan 2001 Corixa and Organon have amended their development agreement for AG 4263
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top